Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Brainstorm Cell Therapeutics

15/05/2025 21:45

Brainstorm Cell Therapeutics Inc BCLI.OQ reported a quarterly adjusted loss of 45 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -75 cents.  The lone analyst forecast for the quarter was for a loss of 97 cents per share.

Reported revenue was zero​; analysts expected zero.

Brainstorm Cell Therapeutics Inc's reported EPS for the quarter was a loss of 45 cents​.

The company reported a quarterly loss of $2.86 million.

Brainstorm Cell Therapeutics Inc shares had fallen by 9.5% this quarter and lost 49.8% so far this year.

FORECAST CHANGES

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Brainstorm Cell Therapeutics Inc is $14.26

This summary was machine generated from LSEG data May 15 at 08:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.97
-0.45
Beat
Dec. 31 2024
-0.38
-0.51
Missed
Sep. 30 2024
-0.57
-0.51
Beat
Jun. 30 2024
-0.52
-0.60
Missed